HOME >> MEDICINE >> NEWS
Long-term benefits found in two drugs for Parkinson's

Two drugs used to treat hallucinations in patients with Parkinsons disease (PD) can not only reduce hallucinations, but may also lead to long-term benefits in these patients, according to a group of Emory University researchers. The long-term benefits may include reduced mortality and a reduced risk of nursing home placement. The drugs studied were the atypical antipsychotics quetiapine (trade name Seroquel) and clozapine (trade name Clozaril).

Jorge Juncos, M.D., associate professor of neurology, Emory University School of Medicine, and colleagues will present their findings at the American Academy of Neurology 54th Annual Meeting in Denver, Colo., on April 18. The research will also appear as an abstract in the April issue of the journal, Neurology.

"Drug-induced psychotic symptoms, such as visual hallucinations, are seen in a significant number of patients with advanced PD," says Dr. Juncos. "Approximately 15 to 20 percent of PD patients may experience these hallucinations over time. They are due to a interaction between the progression of the illness and the drugs used to treat its symptoms," Dr. Juncos explains.

The Emory researchers conducted a retrospective chart review between 1996 and 2001 in 27 patients with advanced PD (mean duration of illness of 13 years, plus or minus six years). Hallucinations had been treated for approximately 36 months using quetiapine in 23 patients and clozapine in four patients.

"We compared the antipsychotic efficacy, mortality and risk of nursing home placement to published historical data (Goetz & Stebbins, Neurology 1996) in similarly affected patients treated with low doses of typical anti-psychotics before 1996," Dr. Juncos says.

Based on clinical exams or caregiver reports, Emory researchers found hallucinations in these patients were reduced by almost half (from 100 to 59 percent) while patients were on one of the study medications. Symptoms of agitation were also re
'"/>

Contact: Janet Christenbury
jmchris@emory.edu
404-727-8599
Emory University Health Sciences Center
18-Apr-2002


Page: 1 2

Related medicine news :

1. Long-term high consumption of red and processed meat linked with increased risk for colon cancer
2. Long-term data show benefit of DETROL LA as first-line therapy for overactive bladder
3. Long-term benefits for newly diagnosed patients with CML receiving first-line therapy with imatinib
4. Long-term obesity linked to loss of brain tissue in women
5. Long-term study demonstrated ADDERALL XR is an effective option to treat adolescents with ADHA
6. Long-term study proves ADDERALL XR is a safe and effective option to treat adults with ADHD
7. Long-term use of antibiotics possibly linked with increased risk of breast cancer
8. Long-term follow-up of mortality in patients with community-acquired pneumonia
9. Long-term outcome of epilepsy surgery is favorable for many
10. Long-term ERT in postmenopausal women with Alzheimers may worsen memory
11. Long-term avoidance of milk in children results in poor bone health

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Long term benefits found two drugs for Parkinson

(Date:11/26/2014)... HealthDay Reporter WEDNESDAY, Nov. 26, 2014 ... understand what they,re saying, a new study suggests they are ... way. Past research has shown that dogs respond to ... and the emotional tone, said study author Victoria Ratcliffe. ... canine brain, according to Ratcliffe, a Ph.D. candidate at the ...
(Date:11/26/2014)... Steven Reinberg HealthDay Reporter ... adults are smoking cigarettes than ever, health officials said. ... about 21 percent in 2005 to 18 percent in 2013. ... million to 42.1 million, despite the increasing population, according to ... However,"we still have a long way to go, and ...
(Date:11/26/2014)... 2014 The Maryland Economic Development ... tenth annual MEDA Awards, which, sponsored by Miles ... Maryland. “The MEDA Awards recognize the individuals, programs ... state. We encourage our members to nominate the ... positive economic impact in the state of Maryland,” ...
(Date:11/26/2014)... November 26, 2014 Increasing demand ... include image guided surgeries has paved way for ... Rising incidence of various types of cancers and ... increase in demand for these owing to their ... contrast media injectors market can also be attributed ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 German scientists ... materials science can cause mesothelioma that looks and acts ... a new article on the research. Click here ... Fraunhofer Institute for Toxicology and Experimental Medicine in Hannover ... While all of the rats eventually developed mesothelioma ...
Breaking Medicine News(10 mins):Health News:Your Dog Really Is Listening to You 2Health News:Your Dog Really Is Listening to You 3Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 2Health News:U.S. Adult Smoking Rate Drops to New Low: CDC 3Health News:Maryland Economic Development Association Seeking Submissions for 2015 Awards 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 2Health News:Contrast Media Injectors Market To 2020 - Global Industry, Growth, Size, Share, Trends, Analysis And Forecast To 2020 Research Report By Grand View Research, Inc. 3Health News:Multi-walled Nanotubes Linked to Mesothelioma in New Study, According to Surviving Mesothelioma 2
(Date:11/26/2014)... November 26, 2014 Investor-Edge has initiated ... VVUS ), Horizon Pharma PLC (NASDAQ: HZNP ), ... (NYSE: JNJ ), and Theravance Inc. (NASDAQ: ... be accessed at: http://investor-edge.com/register . On Tuesday, ... 0.07%, the Dow Jones Industrial Average edged 0.02% lower, to ...
(Date:11/26/2014)... Pa. , Nov. 26, 2014 ... to the development of innovative transdermal synthetic cannabinoid treatments, ... Piper Jaffray 26th Annual Healthcare Conference 2014. The conference ... New York Palace in New York ... will present at 4:50 pm on Tuesday, December 2. ...
(Date:11/26/2014)... and LONDON , Nov. ... market intelligence, MarketResearch.com is pleased to announce the distribution ... Consultancy focusing on the active pharmaceutical ingredient (API) market. ... http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s newest ... Forecast to 2020 , IQ4I analysts ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: